MedPath

Gossamer Bio

Gossamer Bio logo
🇺🇸United States
Ownership
Public
Established
2015-01-01
Employees
135
Market Cap
$206.7M
Website
http://www.gossamerbio.com
Introduction

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.

© Copyright 2025. All Rights Reserved by MedPath